AGTR2
Overview
AGTR2 (Angiotensin II Receptor Type 2) encodes a G-protein-coupled receptor that mediates the effects of angiotensin II. In cancer genomics, recurrent missense mutations in AGTR2 have been observed in ER+ breast cancer, flagging it as a possible therapeutic target. Functional consequences of these mutations in the tumor context remain to be established.
Alterations observed in the corpus
- Recurrent P271L missense mutations observed in 6 ER+ breast cancer tumors in the METABRIC 2,433-sample cohort; flagged as a possible therapeutic target PMID:27161491
Cancer types (linked)
- BRCA (breast cancer): Recurrent P271L mutation in 6 ER+ tumors; proposed as a possible therapeutic target PMID:27161491
Co-occurrence and mutual exclusivity
- No co-occurrence or exclusivity data available in the current corpus.
Therapeutic relevance
- Recurrent P271L mutation in ER+ breast cancer flagged as a candidate therapeutic target; no approved inhibitors established for this indication PMID:27161491
Open questions
- Functional consequences of AGTR2 P271L mutation in breast cancer are unknown; driver vs. passenger status requires experimental validation.
Sources
This page was processed by crosslinker on 2026-05-14.